UNITED THERAPEUTICS Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that UNITED THERAPEUTICS Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $1.48B | Feb 24, 2021 |
| FY2019 | Dec 31, 2019 | $311.10M | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | $401.50M | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $373.60M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | $362.60M | Feb 26, 2020 |
| FY2019 | Dec 31, 2018 | $381.40M | Feb 26, 2020 |
| FY2019 | Sep 30, 2018 | $412.70M | Feb 26, 2020 |
| FY2019 | Jun 30, 2018 | $444.50M | Feb 26, 2020 |
| FY2019 | Mar 31, 2018 | $389.20M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $464.70M | Feb 27, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.18B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.88B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $2.33B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.94B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.69B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.48B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $1.45B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.63B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.73B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.60B | Feb 27, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.57B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $2.07B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.78B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.56B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.38B | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | $282.30M | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | $368.50M | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $346.90M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | $333.50M | Feb 26, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.20B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $984.80M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $727.30M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $475.80M | Feb 21, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.38B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.18B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $979.70M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $555.90M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $593.60M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($187.60M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $805.40M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $814.90M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.06B | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $550.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $481.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $408.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $322.90M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $540.10M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $357.70M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $1.18B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $357.90M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $264.60M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $147.60M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $755.80M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $709.70M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $477.10M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $482.10M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $467.00M | Feb 21, 2024 |
| FY2018 | Dec 31, 2018 | $265.80M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $330.10M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $316.80M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $452.70M | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $381.30M | Feb 22, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.33B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $978.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $802.50M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $598.20M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $755.70M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($206.60M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $778.40M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $474.20M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $643.60M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $520.50M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $246.50M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $230.40M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $138.80M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $120.80M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $59.30M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $83.70M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $184.40M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $86.30M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $38.00M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.88B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.36B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $7.17B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $6.04B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $5.17B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $4.62B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.91B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $3.40B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.88B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.33B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $783.80M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $920.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.18B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.25B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.21B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.22B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.13B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $593.20M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $758.40M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $463.40M | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.10B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $6.44B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $5.98B | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $4.80B | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $3.96B | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $3.40B | Feb 21, 2024 |
| FY2022 | Dec 31, 2019 | $2.78B | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $2.79B | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $2.10B | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $1.85B | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $32.30M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $33.70M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $28.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $28.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $28.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $28.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $31.50M | Feb 26, 2020 |
| FY2018 | Aug 30, 2018 | $17.80M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $13.70M | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.56B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.22B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $6.03B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $5.04B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.32B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.84B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.33B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $3.43B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.85B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.43B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.21B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $961.20M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $894.80M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $738.70M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $738.40M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $669.20M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $705.10M | Feb 26, 2020 |
| FY2019 | Dec 31, 2016 | $1.02B | Feb 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 26 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 21 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 15 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 10 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 11 | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | 3 | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | 4 | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | (11) | Feb 26, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 24 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 19 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 15 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 10 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 11 | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | 3 | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | 4 | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | (11) | Feb 26, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.64M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 44.83M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 47.04M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 46.03M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 45.11M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 44.51M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 43.88M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 43.59M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 43.24M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 42.97M | Feb 21, 2018 |